|
Awareness raising
|
National campaigns to inform decision makers and the general public
|
Patient ‘schools’ on access to treatment and other HCV issues
|
Media notices on HCV
|
Educational videos
|
|
Mobilization
|
Establishing networks of individuals and organizations to advocate HCV issues
|
Implementing letter writing/petition signing campaigns, e.g. a ‘Treatment Waiting List’ and lower price requests to pharmaceutical companies
|
Organizing research and reporting on HCV needs
|
Organizing CSOs to meet with pharmaceutical companies
|
|
Advocacy
|
Encouraging national treatment programs and guideline development
|
Organizing campaigns aiming to bring about favorable policy and response from governments, industry and donors
|
Negotiating lower prices with pharmaceutical companies
|
Specific opposition to pharmaceutical patent applications and support for alternate licensing
|
|
Testing and treatment
|
Conducting screening test campaigns to identify HCV- antibody positive people (that also raise awareness and provide evidence for advocacy)
|
Implementing treatment programs integrated into existing services, particularly for the disproportionately affected/marginalized, e.g. PWID
|
Seeking donor funding for expanded treatment programs using updated protocols
|
Providing community-level and technical input on national program planning and guideline committees
|
